These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 20881268)

  • 1. Specific alterations of microRNA transcriptome and global network structure in colorectal carcinoma after cetuximab treatment.
    Ragusa M; Majorana A; Statello L; Maugeri M; Salito L; Barbagallo D; Guglielmino MR; Duro LR; Angelica R; Caltabiano R; Biondi A; Di Vita M; Privitera G; Scalia M; Cappellani A; Vasquez E; Lanzafame S; Basile F; Di Pietro C; Purrello M
    Mol Cancer Ther; 2010 Dec; 9(12):3396-409. PubMed ID: 20881268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
    Di Nicolantonio F; Martini M; Molinari F; Sartore-Bianchi A; Arena S; Saletti P; De Dosso S; Mazzucchelli L; Frattini M; Siena S; Bardelli A
    J Clin Oncol; 2008 Dec; 26(35):5705-12. PubMed ID: 19001320
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MicroRNA profiling predicts survival in anti-EGFR treated chemorefractory metastatic colorectal cancer patients with wild-type KRAS and BRAF.
    Mosakhani N; Lahti L; Borze I; Karjalainen-Lindsberg ML; Sundström J; Ristamäki R; Osterlund P; Knuutila S; Sarhadi VK
    Cancer Genet; 2012 Nov; 205(11):545-51. PubMed ID: 23098991
    [TBL] [Abstract][Full Text] [Related]  

  • 4. miR-181a is associated with poor clinical outcome in patients with colorectal cancer treated with EGFR inhibitor.
    Pichler M; Winter E; Ress AL; Bauernhofer T; Gerger A; Kiesslich T; Lax S; Samonigg H; Hoefler G
    J Clin Pathol; 2014 Mar; 67(3):198-203. PubMed ID: 24098024
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MicroRNA expression profiling identifies miR-31-5p/3p as associated with time to progression in wild-type RAS metastatic colorectal cancer treated with cetuximab.
    Mlcochova J; Faltejskova-Vychytilova P; Ferracin M; Zagatti B; Radova L; Svoboda M; Nemecek R; John S; Kiss I; Vyzula R; Negrini M; Slaby O
    Oncotarget; 2015 Nov; 6(36):38695-704. PubMed ID: 26497852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MicroRNA-425-5p Expression Affects BRAF/RAS/MAPK Pathways In Colorectal Cancers.
    Angius A; Pira G; Scanu AM; Uva P; Sotgiu G; Saderi L; Manca A; Serra C; Uleri E; Piu C; Caocci M; Ibba G; Zinellu A; Cesaraccio MR; Sanges F; Muroni MR; Dolei A; Cossu-Rocca P; De Miglio MR
    Int J Med Sci; 2019; 16(11):1480-1491. PubMed ID: 31673240
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 4-Acetyl-Antroquinonol B Improves the Sensitization of Cetuximab on Both Kras Mutant and Wild Type Colorectal Cancer by Modulating the Expression of Ras/Raf/miR-193a-3p Signaling Axis.
    Chu YC; Tsai TY; Yadav VK; Deng L; Huang CC; Tzeng YM; Yeh CT; Chen MY
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299137
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Down-regulation of KRAS-interacting miRNA-143 predicts poor prognosis but not response to EGFR-targeted agents in colorectal cancer.
    Pichler M; Winter E; Stotz M; Eberhard K; Samonigg H; Lax S; Hoefler G
    Br J Cancer; 2012 May; 106(11):1826-32. PubMed ID: 22549179
    [TBL] [Abstract][Full Text] [Related]  

  • 9. KRAS mutation signature in colorectal tumors significantly overlaps with the cetuximab response signature.
    de Reyniès A; Boige V; Milano G; Faivre J; Laurent-Puig P
    J Clin Oncol; 2008 May; 26(13):2228-30; author reply 2230-1. PubMed ID: 18445856
    [No Abstract]   [Full Text] [Related]  

  • 10. Combination effect of cetuximab with radiation in colorectal cancer cells.
    Shin HK; Kim MS; Lee JK; Lee SS; Ji YH; Kim JI; Jeong JH
    Tumori; 2010; 96(5):713-20. PubMed ID: 21302618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MTUS1 and its targeting miRNAs in colorectal carcinoma: significant associations.
    Ozcan O; Kara M; Yumrutas O; Bozgeyik E; Bozgeyik I; Celik OI
    Tumour Biol; 2016 May; 37(5):6637-45. PubMed ID: 26643896
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of miRNA -31-3p and miR-31-5p in the anti-EGFR treatment efficacy of wild-type K-RAS metastatic colorectal cancer. Is it really the next best thing in miRNAs?
    Sur D; Cainap C; Burz C; Havasi A; Chis IC; Vlad C; Milosevic V; Balacescu O; Irimie A
    J BUON; 2019; 24(5):1739-1746. PubMed ID: 31786833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations.
    Lee J; Lee I; Han B; Park JO; Jang J; Park C; Kang WK
    J Natl Cancer Inst; 2011 Apr; 103(8):674-88. PubMed ID: 21398618
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lauric acid can improve the sensitization of Cetuximab in KRAS/BRAF mutated colorectal cancer cells by retrievable microRNA-378 expression.
    Weng WH; Leung WH; Pang YJ; Hsu HH
    Oncol Rep; 2016 Jan; 35(1):107-16. PubMed ID: 26496897
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interferon/STAT1 and neuregulin signaling pathways are exploratory biomarkers of cetuximab (Erbitux®) efficacy in KRAS wild-type squamous carcinomas: a pathway-based analysis of whole human-genome microarray data from cetuximab-adapted tumor cell-line models.
    Oliveras-Ferraros C; Vazquez-Martin A; Queralt B; Adrados M; Ortiz R; Cufí S; Hernández-Yagüe X; Guardeño R; Báez L; Martin-Castillo B; Pérez-Martínez MC; Lopez-Bonet E; De Llorens R; Bernadó L; Brunet J; Menendez JA
    Int J Oncol; 2011 Dec; 39(6):1455-79. PubMed ID: 21833472
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Not all antibodies are equal.
    Booth L
    Cancer Biol Ther; 2013 Dec; 14(12):1075-6. PubMed ID: 24317328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Personalized medicine--the future is already here].
    Abadi-Korek I; Shemer J
    Harefuah; 2011 May; 150(5):451-2, 490. PubMed ID: 21678641
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cetuximab-mediated ADCC activity is correlated with the cell surface expression level of EGFR but not with the KRAS/BRAF mutational status in colorectal cancer.
    Seo Y; Ishii Y; Ochiai H; Fukuda K; Akimoto S; Hayashida T; Okabayashi K; Tsuruta M; Hasegawa H; Kitagawa Y
    Oncol Rep; 2014 May; 31(5):2115-22. PubMed ID: 24626880
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Toxicity of Panitumumab After Progression on Cetuximab and Predictive Value of MiR-31-5p in Metastatic Wild-type KRAS Colorectal Cancer Patients.
    Kiss I; Mlcochova J; Bortlicek Z; Poprach A; Drabek J; Vychytilova-Faltejskova P; Svoboda M; Buchler T; Batko S; Ryska A; Hajduch M; Slaby O
    Anticancer Res; 2016 Sep; 36(9):4955-9. PubMed ID: 27630355
    [TBL] [Abstract][Full Text] [Related]  

  • 20. KRAS mutation confers resistance to antibody-dependent cellular cytotoxicity of cetuximab against human colorectal cancer cells.
    Nakadate Y; Kodera Y; Kitamura Y; Shirasawa S; Tachibana T; Tamura T; Koizumi F
    Int J Cancer; 2014 May; 134(9):2146-55. PubMed ID: 24136682
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.